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Abstract - Pharmacoeconomics can play a very important role in decision-making for healthcare structures. In fact, it consists of 
economic evaluation of drugs and treatments for specific diseases. Several techniques exist for this, mainly based on traditional 
management and financial methods as, for example: cost-minimization analysis, cost-benefit analysis, cost-effectiveness analysis or 
cost-utility analysis. The present paper proposes the use of agent based process simulation as an additional tool to assess the 
pharmacoeconomic analysis, in which to incorporate traditional financial tools. This technique allows to compare different 
treatments ceteris paribus, that is by simulating the effects of different drugs and treatments on the same patient, by comparing 
both the medical effects and the economic and financial effects. Last, the paper proposes the case of ozone therapy as a powerful 
use case for this simulative approach, since ozone, a natural gas with antibacterial and anti-inflammatory properties, can 
successfully be used to treat many diseases as an alternative to other drugs and treatments. 
 






Decision-making must necessarily be based on 
prioritization criteria that allow to allocate resources 
efficiently. Consequently, the health professional must have 
the tools to set these criteria when choosing between 
different alternatives. 
One of the many determinants that are intimidating the 
healthcare system is the significant impact that the 
incorporation of new technologies in the health field has. 
This is so much so that it is considered one of the main 
factors responsible for the growth in health expenditure and 
average health care provision. The increase in expenditure 
resulting from the incorporation of technological advances 
has not contributed to the same extent to the production of 
social value for the populations that support it, nor has there 
been such a clear benefit for patients [1]. 
Special mention should be made of the influence that the 
introduction of new drugs into health organisations has had 
on this technological development. This premises make it 
necessary for all those who are part of the health system to 
collaborate. In several countries, measures are being 
evaluated by the public administrations to provide greater 
control over the situation. Among the proposed actions, and 
in the area of system efficiency and expenditure control, the 
importance of incorporating medicines into the health 
system's portfolio of services under cost-effectiveness 
criteria is highlighted. In the same way, the construction of 
pharmacotherapeutic guidelines, as a support for decision 
making, should be based on criteria of evidence and cost-
effectiveness.  
The inclusion of efficiency considerations in decision 
making seems to merge into an axiom that, although not 
characterized by its uniqueness, is becoming more and more 
evident [2]. Since the early 1990s, in Australia and Canada, 
and especially with the establishment in the United 
Kingdom of the British National Institute for Health and 
Clinical Excellence in 1999, known as NICE, which 
includes evaluation in the selection of health innovations, 
the adoption of economic evaluation in decision-making has 
become an imminent necessity, to which an appropriate 
response of a practical and applicable nature must be given 
[3]. 
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In this sense, pharmacoeconomy [4] seems to emerge, 
becoming a cardinal discipline in the health scenario. 
Pharmacoeconomy provides professionals with information 
on all the economic aspects in the health sector, providing 
them with a broader perspective in the analysis of all the 
implications of the drug through specific methodological 
tools. 
Within the pharmacoeconomical analyses, are included 
economic evaluations, techniques that allow professionals to 
calculate the efficiency in terms of the relationship between 
the costs and consequences of alternative interventions [5]. 
The reality of the application of the pharmacoeconomy 
in daily practice can be seen reflected in recent studies such 
as that carried out by Catalá-López [6]. 
The number of economic evaluations of health 
interventions is increasing, with a maximum growth in the 
last five to ten years. The scope of most of the studies 
analysed was in specialized care. With these data, it seems 
clear that the use of economic evaluations is becoming 
increasingly essential in the healthcare sector. The main 
reasons, documented by the health professionals themselves, 
that make it difficult to implement effective decision-
making criteria are, on the one hand, the difficulty of 
understanding this type of study or the approach that they 
usually take and, on the other hand, the fact that it is far 
removed from daily practice. Other arguments that question 
the credibility of economic evaluations are that these studies 
are, in most cases, financed by the pharmaceutical industries 
and arise from the mistaken idea of understanding economic 
evaluations as purely savings and not quality improvement 
tools. Once the problems are circumscribed, only the 
implementation of solutions is possible. Thus, and after 
defining a framework in which the application of 
pharmacoeconomics seems to be an increasing value in the 
healthcare environment, but which still needs to be 
encouraged, it is necessary to establish instruments that 
allow to confront the problems that still seem to be felt for 
their use in clinical decision-making. For this reason, 
simulation is proposed as a tool both to teach 
pharmacoeconomics and a to actually compare the 
effectiveness and actual economic impact of different 
alternatives. 
In particular, the use of ozone in medical therapies is 
chosen as proposed a use case for the present analysis. This 
is because ozone, a natural substance, has proven to be an 
outstanding alternative to standard treatments in a wide 
spectrum of diseases, with effective results and potentially 
with direct and indirect cost reductions both for the medial 
structure and for the patients. 
The first part of the work will introduce 
pharmacoeconomics as a technique for comparing 
treatments and hence as a management strategy for 
economic evaluations in the healthcare sector. The second 
part will deal with ozone and its use in medicine. The 
discussion will propose several simulation techniques that 
could support pharmacoeconomic analysis, with specific 
regard to the use of ozone in alternative to other standard 
treatments. 
 
II. PHARMACOECONOMICS AND ECONOMIC 
EVALUATIONS WITHIN HEALTHCARE 
 
The application of the knowledge and techniques of 
business management and economic evaluation to the field 
of healthcare makes it possible to focus the analysis on the 
treatment of the problems posed by an appropriate 
prescription both from the point of view of effectiveness in 
terms of health and of efficiency, thus obtaining a social 
benefit at a reasonable cost. Pharmacoeconomics is 
therefore a useful tool for measuring the effects of decisions 
on available resources and also on the possibilities for 
quantifying the health impact of a health intervention. As a 
result of the current approach of the health authorities to 
pharmaceuticals, the pharmaceutical industry worldwide has 
begun to take an interest in these analytical techniques and 
to use them to develop its research-development, production 
and marketing strategies for its products. The economic 
evaluation of medicines is not a panacea for the problems 
faced by health professionals on a daily basis, but it does 
make it possible to reduce the arbitrariness of decision-
making on the use of available resources, so that it is an 
indispensable instrument for improving health practice and 
achieving better results at an affordable cost for a country's 
economy [7]. 
A medicine [8] can be defined as a pharmaceutical 
preparation or formulation used for the prevention, 
diagnosis and/or treatment of a disease or pathological 
condition, or to modify physiological systems for the benefit 
of the person to whom it is administered. Although 
medicines alone are not sufficient to provide adequate care, 
they play an important role in protecting, maintaining and 
restoring health. 
Medicines are not only an essential component of health 
care, a symbol of treatment, but also a commodity and a 
commodity of modern industry, a commodity and a 
commodity to be traded and sold. 
As an input for health actions, they represent a cost that 
has significant repercussions on official budgets and on 
people's budgets. 
From the economic point of view, medicines are 
consumer goods that are those products made to be used, 
both for productive consumption and for personal 
consumption. Therefore, the drug can be defined as a 
product, as any material good that has value for the 
consumer or user, and is capable of satisfying a claim and 
reporting a monetary income to the producer. 
Medicines are important inputs in health services and are 
the subject of commercial transactions. They are obtained 
from community pharmacies and a high proportion of their 
income is used to purchase them. As the relationship 
between the medicinal product as a marketing object and its 
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value in use is so decisive that it gave rise to the concept of 
the medicinal product as a "social good" [9]. 
The modalities and reasons for medical consumption are 
conditioned by a number of interacting factors, including: 
therapeutic and prescribing practices, the attitude of patients 
towards physicians, the perception of the population with 
regard to medical properties, the economic resources of 
individuals, the availability of public and private funds for 
their purchase and distribution, and the promotional 
activities of the pharmaceutical industry. Employment is 
also determined by cultural aspects and other specific 
characteristics of the consumer population, such as 
prevalent diseases and available technological and economic 
resources. 
On the other hand, in our days, the attention of the health 
is the subject of intense commercial activity which leads to 
the excessive consumption of its services and, in particular, 
to the use of all technological resources. These conditions 
reinforce the role of medicines. 
The lucrative nature of the industrial activity of drug 
production and marketing has led to major diversions such 
as the production of unnecessary, ineffective or toxic drugs, 
irrational prescription, self-medication, etc. This, in turn, 
affects teaching, information and consumption activities. 
The medicinal product has become a complex element 
whose use involves considering not only the 
pharmacotherapeutic, health and social aspects but also 
those of an economic, industrial, financial and commercial 
nature. Thus, there is a need to devise a policy that 
harmoniously links industry and commerce on the one hand, 
and the consumer, the doctor and the health authority on the 
other. Most countries [10] face a shortage of resources in the 
area of health, which forces them to contain, redirect and 
rationalize their expenditures. 
This situation and the absence of a defined policy and 
programmes lead to serious problems in financing the health 
care system, with the consequent increase in private 
spending and a decrease in resources allocated to 
pharmaceutical assistance. This is even more serious in 
developing countries, where there is also a shortage of 
hospitals and health centres that serve the neediest sectors of 
the population. Insufficient availability of medicines, 
medical and surgical supplies and other inputs in public 
services has a negative impact on the quality of care and the 
use of services. 
This situation has resulted in the current emphasis on 
assessing the social and economic impact of medicinal 
products, while taking into account the technical and 
scientific aspects of their efficacy, safety and quality. In this 
context, new proposals have been generated for the 
development of the pharmaceutical area under the concept 
of socioeconomic evaluation of medicines [1,3]. 
Among the various aspects that should be considered in 
this context before authorizing their introduction to the 
market, the following may be mentioned: potential for 
inducing self-medication, therapeutic indications in relation 
to prescription habits, possibilities generated by the forms of 
presentation of the physician in terms of compliance or non-
compliance with the treatments and the influence that the 
system of care will have on their use, as well as the cost of 
the treatment in relation to others. Evaluations of this nature 
would be important in health care systems for the use of 
smaller forms. 
With regard to the economic and financial aspects of the 
use of medicines, the evaluation should be based on a 
relative consideration of cost, benefit and risk. The 
incorporation of new drugs into a country's health system 
and market should take into account these financial and 
economic aspects of drug use. 
In order to evaluate the use of medicinal products, from 
a more global point of view and not only in 
pharmacotherapeutic terms, it is necessary to carry out 
economic evaluations of medicinal products. Economic 
analyses of this type, referring to specific drugs or drug 
classes or types, should be published as any other research 
result and be publicly accessible or, perhaps, it would be 
necessary for such information to be provided in 
conjunction with information on efficacy and safety in 
relation to indications, dosage of use, treatment time and so 
on. In fact, it is a question of the comparison between 
pharmaceutical products and other treatment methods with 
regard to their therapeutic properties and the costs of their 
use as alternative native methods, and the feasibility of 
applying economic concepts of cost/benefit to decision-
making in the pharmaceutical sector [1]. 
These types of pharmacoeconomic studies have 
introduced relative drug evaluation mechanisms, whereby 
different medicines are compared and therapeutic 
substitution between therapeutically similar products (even 
if they are made up of different active ingredients or 
different pharmaceutical forms and have the same active 
ingredients) is assessed. 
The economic evaluation of drugs - whose synonym is 
pharmacoeconomics - can be expressed as the application of 
economic analysis to the field of medicine; and it can also 
refer more specifically to the application of economic theory 
to pharmacotherapy. Since all evaluation is based on 
comparison, economic evaluation of drugs could be defined 
as the determination of the efficiency (cost-benefit ratio) of 
a drug treatment and its comparison with other options in 
order to select the most cost-effective treatment. 
In this way, the economic evaluation of measures can 
contribute to harmonizing the growing health needs of the 
population with the available economic resources. The 
selection of a given therapeutic option according to its 
efficiency; that is to say, considering its costs and benefits 
simultaneously, was a considerable advance compared to 
other more partial criteria. 
The efficiency criterion [11] is applicable by different 
actors in different areas of healthcare domain. Recent 
international experiences [12, 13, 14, 15] show that 
economic evaluation techniques for medicines are becoming 
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increasingly important in health decision-making, providing 
invaluable help in making them based on more rational, 
objective and transparent criteria. 
The economic evaluation of medicines usually employs 
the traditional methods of economic analysis [16], which 
means that all professionals working in the field and 
interacting information from it need basic knowledge of the 
terms and concepts that are currently the common 
denominator of both economic evaluation and health 
economics. For this reason, pharmacoeconomics is an 
activity that requires multidisciplinary teams and, in fact, a 
high proportion of analysts who carry out studies in this 
field are not economists but come from the field of health 
sciences, statistics, operational research, etc., and have often 
not had a formal apprenticeship in economic disciplines. 
In this way, the knowledge of the pharmacoeconomic 
concepts on the part of professionals working in both the 
health system and the pharmaceutical industry makes it 
possible to introduce an economic culture into their usual 
tasks; that is, to consider the existing relationship between 
the costs and the results of the pharmacotherapy used 
(Figure 1). 
 
 Figure 1. The two sides of Pharmacoeconomics 
 
From a clinical perspective, the use of a technology is 
justified if its effectiveness (the achievement of a target 
under real conditions) or at least its effectiveness (the 
achievement of a target under ideal conditions) is positive. 
However, from an economic perspective, the emphasis is on 
efficiency. 
Thinking in terms of efficiency implies considering the 
effectiveness of a process in relation to the resources it 
requires. The reason is obvious, given that resources are 
limited with respect to their possible applications, the fewer 
resources are needed to achieve a given objective, the better; 
as this will make more resources available for other health 
purposes. 
At present, and given the high cost of developing a new 
product, there is a clear vocation and orientation within 
pharmaceutical companies to provide increasingly efficient, 
effective, better tolerated and higher quality drugs, which 
will represent a clear advance and improvement within the 
available pharmaceutical arsenal. For this reason, within the 
pharmaceutical industry, medical economic evaluation 
analyses are increasingly being designed and carried out 
throughout the entire life cycle, both during the early stages 
of their development and once they have been 
commercialized. This fact reflects the need to prioritize the 
investment of existing resources, and to choose drugs that 
are the most cost-effective and therefore achieve the best 
therapeutic benefit at the lowest possible associated cost. 
In industrialized societies capable of regulating and 
controlling the production costs of health goods and where 
health coverage is almost total, pharmacoeconomics can 
certainly help to improve clinical decision-making [1], 
especially when it comes to choosing between several 
similar treatments. Every exercise, however, must be 
focused on the perspective not only of controlling costs, but 
also of improving efficiency in order to achieve equity in 
access to health services. 
 
III. THE USE OF OZONE AS A MEDICATION AND IN 
DIFFERENT SECTORS 
 
In 1896, Tesla [17] issued a patent for an ozone 
generator using metal plates. He founded the Ozone Tesla 
Company and began manufacturing these units. His clients 
were naturopaths and allopates who welcomed this 
invention well. The respiration of ozone through olive oil 
and other oils was widely practiced at the time. Tesla 
produced a gel made from ozone bubbles through olive oil 
until it solidifies, and sold it to doctors. 
Let's think about what happens when our body lacks 
oxygen and is assaulted by fatigue, circulatory disorders, 
digestive difficulties, muscle pain and the collapse of the 
immune system. From here you can see how beneficial 
oxygen ozone therapy is which is a medical practice deputed 
to carry oxygen and especially ozone (three oxygen atoms) 
to increase the ability of our body to use this gas. 
The fields of use are vast: from the now famous 
application in the hernia of the disc to the most recent one in 
the field of oncology and pain therapy. And again in 
dementias; in the treatment of bacterial and viral 
inflammations and in the aesthetic and dental field. 
Ozone oxygen therapy finds its development and 
validity in being a therapy with low costs and with very high 
benefits. It has been practiced for years, but it has always 
remained a niche therapy. It is an "intervention" that has no 
side effects, as it is performed with oxygen, which is one of 
the fundamental elements for the life of our organism that is 
converted into ozone, gases with high healing properties. 
Furthermore, ozone therapy has no contraindications even if 
it must be practised by specialists who know the treatment 
protocols, the dosages to be used, the number of sessions 
and the frequency with which they can be repeated. 
In order to precisely define the toxicity of a gas, it is 
necessary to establish:  
1. Concentration  
2. exposure time  
3. route of administration 
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Ozone therapy is one of the methods with the lowest risk 
of side effects (Jacobs clinical trial 1981). Fundamental 
rules for operating in complete safety are: 
1. correct administration: scrupulously following the 
protocols 
2. use of suitable equipment certified and revised 
3. the use of a gas with a low risk of side effects. Not 
to be inhaled 
4. Not too pain. Good ozone therapists must not cause 
pain. Pain can trigger even uncontrollable vagal reactions 
The routes of administration of ozone are as follows: 
• Great Autohemoinfusion or, better, Systemic 
Oxygenation: metabolic rebalancing, better use of body 
oxygen, correction of circulatory ischaemia, detoxification 
from toxins and free radicals, increased resistance to stress, 
immunomodulating action, treatment of bacterial/viral 
infections, even antibiotic-resistant, action on the 
microcirculation, including the brain, neurodegenerative 
diseases. 
• Small Autoemoinfusion: immunomodulating, 
antiviral, herpes zoster, and simplex, acne, fibromyalgia, 
antidepressant action. 
• Subcutaneous: muscle decontracting, cellulite, 
reactivation of the venous circulation, lipolytic action.  
• Intramuscular: decontracting, herniation and disc 
protrusion. - In particular: limbs, arthrosis. - Insufflation 
(rectal, vaginal, uterine, urethral): Gae replacement, 
analgesic treatment, treatment of infections, fibromyalgia. 
• Topical route: ulcers, sores, muscular contractures, 
acne, venous insufficiency, oral treatments, cellulite, 
treatment of skin spots. 
• Hydropinic: body water rebalancing, dysbiosis, 
helicobacter pylori. 
Ozone is a natural gas universally known for its 
microbial properties. It kills bacteria by cell lysis by 
attacking the protective membranes with an oxidative 
mechanism and altering their internal enzymes, without 
leaving chemical residues. Viruses are first inactivated and 
then physically destroyed, while in others Ozone enters into 
the depths and damages viral nucleic acids by preventing the 
replication mechanism. Moreover, as far as organic 
molecules are concerned, they are attacked by ozone with 
the oxidizing action of atomic oxygen (O) or through the 
formation of unstable compounds (Ozonoids) that lead to 
the breakage of the molecules themselves. 
Ozone is also able to reactivate circulation and 
microcirculation. In particular: 
• it increases erythrocyte deformability and 
filterability, because it breaks down the long chains of fatty 
acids through controlled lipoperoxidation; 
• it increases the production of 2.3-
diphosphoglycerate with greater oxygen transfer to 
peripheral tissues; 
• it reduces platelet aggregation and plasma 
viscosity; 
• it reactivates energy metabolism at mitochondrial 
level with an increase in the production of ATP. 
The primary purpose is to try to interrupt the involutive 
cycle of degenerative events by inducing the cells to 
reactivate the synthesis of Oxidative shock proteins (osp). A 
good percentage of patients show a significant improvement 
(figure 2) due to a beneficial influence on circulation, 
oxygenation, mood tone and attention. 
 
 Figure 2. Reactivation of the synthesis of Oxidative shock proteins 
 
The interpretation of the test concerns the following 
points: 
- Following treatment with ozone, an increase can be 
observed significant concentration of oxygenated 
hemoglobin 
- The effect is only visible at least one hour after the 
start of the treatment. 
- At the same time, non-oxygenated hemoglobin 
remains almost constant, indicating an increase in cerebral 
oxygenation for the same oxygen consumption. 
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- Therefore, a situation improved in the 
functionalities because it is better to capture the oxygen 
present. 
 
The whole thing translates into: 
1. improvement of brain microcirculation 
2. increased attention 
3. improvement of cognitive activities and memory 
4. reduction of neuromuscular spasticity 
5. anti-aging 
 
Ozone also has an anti-inflammatory and pain-relieving 
action; improving oxygenation, inhibiting leukocyte and 
platelet activation and adhesion, inhibits the activation of 
phospholipase A2, cyclooxygenases and metalloproteinases. 
This will inhibit the bio-humoral inflammatory response. In 
particular we have: 
- Inhibition of prostaglandin pro-inflammatory 
synthesis; 
- Inhibition of the release of bradychidine and 
algogenic compounds; 
- Neutralization of endogenous ROS and stimulation 
of local production of antioxidant enzymes. 
 
Another medical field in which ozone therapy has great 
success is hernia disc treatment [18]. As regards oxygen-
ozone injections into the spinal column area, the ministerial 
circular of 20 January 2005 reiterates that '[...] intradiscal 
and/or intraforaminal injections can only be carried out 
experimentally (and therefore free of charge) in accredited 
hospital facilities and always in the context of controlled 
clinical trials [...]'. The only route of administration 
approved by the Higher Institute of Health is the 
paravertebral route. In figure 3, the results are shown from a 
study conducted on 7.253 patients. 
 
 Figure 3. Results from a study about hearnia disck treatment with ozone 
 
A very topical issue where ozone can also be very 
interesting is that of antibiotic resistance [19]. The 
phenomenon of antibiotic resistance in bacteria attacking 
our organism is becoming increasingly worrying. This is 
demonstrated by the recent scientific reports [20] from the 
United States on the presence, in the urine of a 49-year-old 
from Pennsylvania, of a strain of escherichia coli resistant to 
Colistin, the most powerful antibiotic in circulation, the 
drug used in extreme cases of infection of bacteria capable 
of "killing 50% of those affected", according to experts of 
the American society for microbiology. 
According to Thomas R. Frieden [21], director of the 
Centres for Disease Control and Prevention, a public health 
organization in the United States, "we have entered a post-
antibiotic era in which we may have to rely less and less on 
these drugs that, for decades, have saved millions of lives. 
The main culprit of antibiotic resistance is the mcr-1 
gene, first identified by Chinese researchers in November 
2015 [22], which can put bacteria in a position to resist the 
most potent chemical drugs. The study had identified the 
gene in common but potentially fatal bacteria such as 
escherichia coli and klebsiella pneumoniae, responsible for 
pneumonia and blood diseases. A gene that could 
unfortunately spread easily in other bacterial strains, 
creating new types of so-called superacteria. 
Faced with what could take on the form of a global 
emergency in the coming years, there are two possible 
solutions: to continue investing in the production of 
increasingly effective antibiotics, or to encourage the use of 
alternative therapies capable of complementing chemical 
drugs. One of these alternatives is ozone therapy, since there 
is no bacterium, virus or fungus that can withstand a correct 
dose of ozone, administered in the right times. In fact, at the 
cellular level, bacterial resistance to antibiotics depends on 
several factors, first of all the structural change of the 
superficial envelopes of the bacterial cell, which reduces the 
penetration of antibiotics. In gram-negative bacteria 
resistance may be due to alterations in the protein membrane 
through which many antibiotics penetrate. 
In other cases, the bacterium is able to expel the drug, 
which has already entered the cell, thanks to efflux pumps 
that operate coupled to a particular type of protein. It can 
also happen that the target of the antibiotic is altered and 
therefore no longer recognized by the drug or that the 
antibiotic loses its biological activity because inactivated by 
some specific enzymes produced by both bacteria of gram 
positive and negative type. 
About 5.7% of all types of klebsiella pneumoniae 
isolated in Europe in 2014 were resistant to all groups of 
antimicrobial agents normally used. In addition, more than 
80% of these were reported in Greece and Italy. 
A problem which, again, ozone therapy can remedy. 
Ozone, in fact, kills bacteria by cell lysis, attacking their 
protective membranes, with an oxidative mechanism, and 
altering their internal enzymes without leaving chemical 
residues. A mechanism similar to that used by white blood 
cells during bacterial phagocytosis. 
Ozone is a powerful oxidizer and an important 
disinfectant that acts on microorganisms through the 
oxidation of their biological material. It has been shown that 
ozone can be used as an antibacterial agent in various forms 
such as ozonized saline solution, ozonized water, ozone 
MARCO REMONDINO et al: PHARMACOECONOMICS AS A MANAGEMENT AND FINANCIAL STRATEGY IN .. 
DOI 10.5013/IJSSST.a.19.04.28                                            28.7                             ISSN: 1473-804x online, 1473-8031 print 
associated with particular oils or other types of substances, 
and, more frequently, the gaseous mixture of oxygen and 
ozone. Most studies on oxygen-ozone therapy have shown 
that ozone, when used in vitro, could destroy all types of 
bacteria, positive gram and negative gram. In addition, this 
research indicates that the susceptibility of microorganisms 
to antibiotics increases when ozone is used, as does the 
effectiveness of the immune system. 
 
IV. AGENT BASED SIMULATION AS A POWERFUL 
SUPPORT TOOL FOR PHARMACOECONOMICS 
 
The healthcare context is particularly complex as it is 
characterized by high quality standards, low management 
costs and management of assets, material and immaterial, 
bound to the criteria of efficiency, effectiveness and 
economy defined in the central planning following the 
various reforms of the sector; the rules of "supply" and 
"demand" at the base of this sector cannot simply be traced 
back to the classic functional paradigms of commercial 
systems but are determined in a complex manner by a series 
of factors difficult to analyse, summarize and define. In this 
context, in order to be able to manage these systems in the 
best possible way, new techniques of analysis and 
management are needed, and this is the focus of the study. 
The most widespread methods of analysis and management 
of systems in the healthcare environment are ex-post or ex-
ante; these techniques are not effective in a dynamic and 
complex context such as healthcare, as they do not allow to 
have real-time information on the behaviour of the system 
analysed or to bring the necessary corrective actions 
reasonably quickly. Real time data analysis techniques exist, 
but are poorly applied in this context, given their difficulty 
of use in environments with high variability and uncertainty. 
In the healthcare context, when we speak of a management 
and control system, we commonly speak of Business 
Intelligence systems; with this term we refer to systems that 
allow the collection of data with the purpose of analysing 
the past activities of an organization in order to understand 
its functioning, its problems and try to evaluate its 
performance and estimate its future functioning. One of the 
main criticalities that is created with these systems is that 
they are fed with data collected asynchronously to the time 
of the evaluation and therefore function as internal reporting 
systems that can provide information on the past behaviour 
of the system and predict its future behaviour on the basis of 
information that does not necessarily reflect the current 
behaviour of the system and therefore, may not make sense 
from the point of view of management analysis. 
The purpose of the present paper is to propose the use of 
agent based process simulation (ABPS) as a decision 
making tool for pharmacoeconomic analysis and, 
particularly, for the analysis of ozone therapy treatments 
when compared to traditional ones. The purpose is twofold, 
since the simulation can be a great decision making tool, but 
also a great descriptive tool to practically show the 
outcomes of a certain strategy.  
First and foremost, Agent-based simulation (ABS) is 
selected as the base method for simulating situations of 
pharmacoeconomics. This is because ABS has proven to be 
a tremendously useful technique for modelling complex 
systems [23]. Through agent-based simulation, the modeller 
explicitly recognizes that complex systems, and in particular 
social systems, are the product of individual behaviours and 
their interactions. What distinguishes agent-based 
simulation from other modelling techniques is the way in 
which the first abstraction of the real system is constructed 
and, consequently, the formal model, especially using a 
metaphors based approach [24] (figure 4), a powerful 
method able to represent a real situation in a simulation 
models by means of metaphors and then interpreting the 
simulated results by means of an inverse function of those 
metaphors. In formal models constructed through agent-
based simulation, the basic components of the actual system 
are explicitly and individually represented in the model. 
 
 Figure 4. From the real situation to the simulation model (and from 
simulated results to realistic ones) 
 
The use of ABS is complemented by some parts of the 
model (the most deterministic ones) that can be modelled by 
a process based approach. This is what is referred to as 
ABPS approach [25]. 
The use of simulation as a tool for pharmacoeconomic 
analysis allows the inclusion of a greater number of 
variables and entities, as well as the representation of their 
behaviour over time, thus allowing the model developed to 
be more closely linked to reality than any other modelling 
technique such as mathematical ones or even medical ones. 
One of the main components in a simulation model are the 
entities that are going to be simulated, for the case of the 
pharmacoeconomic analysis, most of the times the entities 
are the patients that suffer from the disease under study, 
however, it may be the case that the entities of the model are 
of another type, for example medical units or doctors that 
attend to a certain condition, this depends on the approach 
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that one wishes to give to the study in progress. Unlike a 
Markov model, where the focus is primarily on the overall 
model results or states, in a multi agent based model the 
patient could be an explicit element of the study. Each of the 
entities within a simulation model has different attributes 
that determine the way in which they behave during the 
simulation. 
These attributes have certain initial values and are 
modified over time depending on the rules established when 
designing the model, for example, when studying a person 
with diabetes, one of the attributes that they have is the 
weight they had at the time they were diagnosed with the 
disease, however, this variable changes over time depending 
on the type of treatment the patient follows, the 
complications that occur or the eating habits they have. It is 
important to stress that the rules of change and implications 
for patient attributes must be studied and clearly defined so 
that the results obtained are valid and can be interpreted 
appropriately. It is important to emphasize that each of these 
changes can be assigned a monetary value that serves as an 
indicator in the pharmacoeconomic analysis. 
When using agent based simulation as an analysis tool, 
the rules of change of state of patients should be included, 
depending on some global variable, for example, in the 
particular case of ozone therapy applied to osp, the synthesis 
of Oxidative shock proteins may function as the main 
indicator of the health of a given patient, depending on this 
level will be the treatment received, the complications that 
may arise due to the condition of this disease, the type of 
treatment to be followed or even the mortality rate. As 
mentioned above, all of these changes need to be recorded 
in order to determine what the costs of treating a given 
disease are. A pharmacoeconomic analysis can also be used 
to study the allocation of non-monetary resources. For 
example, how many beds are needed for an epidemic that 
may occur at any given time, or how many specialist doctors 
must be on hand to care for patients with some type of 
cancer. Through the use of agent based simulation it is also 
possible to make a study of different scenarios, for example, 
when dealing with some type of disc hernia, it is possible to 
design a model in several versions, where the change is the 
type of treatment a patient receives, and the results also 
impact other factors, like for instance the time they’ll need 
to stay away from work. Hence, the simulation is presented 
as a tool for comparison between different scenarios. 
Use a agent based model for pharmacoeconomic 
analysis of complex diseases has a number of advantages 
over other methods. As already mentioned, it is a less 
restrictive and more flexible technique than decision trees 
and the Markov strings with discreet status space, as it 
allows to enter a number of variables as well as the rules 
that produce a change in the system over time, thus 
generating a model that is more closely linked to the reality. 
Besides, it is possible to use probability distributions in 
different ways, depending on the of the input data available 
(and historical data). In addition to the fact that through the 
realization of several replications (coeteris paribus) a 
scenario which is statistically significant can be obtained. It 
is a model that is easy to implement as there is no need to 
force the evolution of the disease in mutually exclusive 
states or force it to change at certain time intervals. In 
addition to the fact that it can reduce the time needed to 
draw conclusions instead of conducting medical studies that 
may take more time and require a greater allocation of 
resources. It is a straightforward model, since all the 
components and entities are part of it. the model, contrary to 
what would happen in the other methods in which patient 
characteristics are not a definite part of the model, plus that 
accurate time control is being maintained. It is possible to 
vary the structure of the model and thus to analyse several 
scenarios, which are which would not be possible with 
clinical trials or other methodologies. Global and 
differentiated statistical estimators of costs are obtained 
based on in the resources consumed, the simulated scenario 
and the processing followed. Statistical techniques can be 
used to analyse the outputs of the simulation experiments. 
Time is explicitly considered within the event simulation the 
behaviour of variables and entities can be modelled in a 
discreet manner, thus making it possible to the length of the 
simulation. Simulation also allows the analysis of different 
scenarios and the implications of the same, thus being a 
powerful tool for decision making. By simulating what 
happens in a health care system by treating a certain a more 
realistic view of the implications of this disease is acquired. 
complications or doses of medicines, such as the 
complications involved. necessary for their treatment, 
influencing the actions to be taken such as the prevention or 
faster response to certain events. Although there is no 
complete information available on the functioning of the by 
means of the simulation it is possible to make reliable 
estimates about the performance. 
 
V. QUALITATIVE DESIGN AND RESULTS OF A 
SIMULATION MODEL FOR OZONE THERAPY 
PHARMACOECONOMIC ANALYSIS 
 
As stated in previous sections, ozone therapy has a very 
wide range of powerful and effective applications, hence it’s 
impossible to think about a single (generalist) simulation 
model to embrace them all. For each specific case, a 
simulation model has to be created and tuned, as to 
variables, parameters, rules and entities. The purpose of the 
present section is to qualitative describe the simulation 
framework that could be used for a pharmacoeconomic 
evaluation of ozone as an alternative treatment of several, 
different diseases.  
Patients are randomly generated, each of whom is 
assigned physical characteristics based on the information 
obtained from past clinical studies. Each patient is replicated 
to simulate it in each of the two designed scenarios 
(treatment with ozone vs treatment with traditional therapy). 
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A third scenario could be used, which is the one in 
which the patient does not follow any type of treatment for 
the disease, so to benchmark both results against a “zero 
treatment”, which could serve as a basis for comparison of 
both costs and complications for both the other treatments. 
For each of the scenarios, rules are defined that model 
the appearance of complications depending on the time the 
patient has suffered from the specific disease and whether or 
not she has undergone any treatment before. A statistically 
significant number is defined for the total number of 
patients to be simulated. As well as the number of replicas 
that will be made of the model, this in order to obtain 
statistically significant estimators.  
A compilation of costs of the different treatments, 
presented throughout the simulation, is made by statistical 
analysis and a comparison is carried on between the 
scenarios. 
The whole simulation logic is represented in figure 5. 
 
 
 Figure 5. The simulation framework 
 
VI. CONCLUSION AND FUTURE DIRECTIONS 
 
The purpose of the present work is twofold. First, it aims 
to discuss the use of simulation as a tool for 
pharmacoeconomics, a powerful decision making analysis 
for healthcare sector. To this extent, pharmacoeconomics is 
presented in detail, with its features and fields of 
applications. Besides am agent based approach is proposed 
for the simulation, enriched by parts managed with a more 
traditional process simulation approach and, schematically, 
a logical flow is proposed, starting with the generation of 
patients, the definition of specific attributes for them, 
derived from real world data and the consequent passing 
through three simulated scenarios. “Scenario 0” is the base 
one, that is the one where the patient is not undergoing any 
treatment for her disease, while “scenarios 1 and 2” are 
those where the patient is treated with the two alternative 
drugs/medical cares. 
The second purpose of the work is to propose to the 
scientific community the pharmacoeconomic evaluation, by 
means of simulation, of ozone as a treatment in alternative 
to other, traditional, medical cares. For this reason, the paper 
synthetically presents a range of uses for ozone, a natural 
gas, where it proved to be an effective alternative to other 
treatments, being safe and effective as an antibacterial, anti-
inflammatory, decontracting and oxygen vehicle [26]. 
Since there are more and more medical applications for 
ozone therapy, it can be really interesting to evaluate its use 
by means of pharmacoeconomics and this makes it the ideal 
candidate for the novel approach proposed in this paper. 
Future works will take care of real situation, by applying 
the proposed methodology to use cases, hence assessing 
both the medical side of the issue (the validity of ozone as a 
cure for several diseases) and the management side, that is 
the possibility of using a cheaper medication. Not to 
mention that ozone, being a natural gas, has no impact on 
the environment, making it a potential source of 
sustainability. 
Hence simulation applied to pharmacoeconomics 
appears to be a really interesting decision making method 
for healthcare structures and the case of ozone therapy needs 
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